Stoke Therapeutics (STOK) Invested Capital: 2022-2025
Historic Invested Capital for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $308.1 million.
- Stoke Therapeutics' Invested Capital rose 32.74% to $308.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year increase of 32.74%. This contributed to the annual value of $229.0 million for FY2024, which is 43.53% up from last year.
- Per Stoke Therapeutics' latest filing, its Invested Capital stood at $308.1 million for Q3 2025, which was down 8.01% from $334.9 million recorded in Q2 2025.
- Stoke Therapeutics' Invested Capital's 5-year high stood at $350.1 million during Q1 2025, with a 5-year trough of $140.3 million in Q1 2024.
- In the last 3 years, Stoke Therapeutics' Invested Capital had a median value of $229.0 million in 2024 and averaged $234.0 million.
- Its Invested Capital has fluctuated over the past 5 years, first crashed by 34.37% in 2024, then spiked by 149.44% in 2025.
- Quarterly analysis of 4 years shows Stoke Therapeutics' Invested Capital stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then surged by 43.53% to $229.0 million in 2024, then skyrocketed by 32.74% to $308.1 million in 2025.
- Its Invested Capital was $308.1 million in Q3 2025, compared to $334.9 million in Q2 2025 and $350.1 million in Q1 2025.